As expected, iGMFI levels of mTNFα+ on CD14+ cells from RA patients in remission after infliximab were comparable to those from RA patients in remission after adalimumab, but they were significantly different from those of HDs (41.99 ± 16.28 for infliximab, 20.62 ± 4.02 for adalimumab and 715.4 ± 144.6 for HDs; P < 0.01). Here, CD14 is linked to rheumatoid arthritis.